Drug Delivery Landscape in Cancer Research
- 1st Edition - April 3, 2025
- Imprint: Academic Press
- Editors: Ranjita Shegokar, Yashwant Pathak
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 2 9 1 6 8 - 5
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 9 1 6 9 - 2
Drug Delivery Landscape in Cancer Research examines the combined impact of prevention, diagnosis, and treatment of cancer. With a strong focus on the status, challenges, and prospe… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteDrug Delivery Landscape in Cancer Research examines the combined impact of prevention, diagnosis, and treatment of cancer. With a strong focus on the status, challenges, and prospects of cancer drug delivery technology, the book examines clinical translation-related knowledge and the development of different organ related cancers. In 22 chapters, it describes current and new drug delivery systems in twenty different cancers and gives insights into drug delivery strategies and tumor microenvironment management in oral and ocular cancers. This book is a timely and valuable resource for health professionals, scientists, researchers, health practitioners, students, and anyone who wants to broaden their knowledge.
- Contains current studies of the targeted use of drug delivery systems based on the microenvironmental properties of different cancer types
- Provides essential information on the most recent drug delivery systems available for different cancer types
- Explains current technology and its applications to drug delivery in cancer
- Contains contributions from oncologists, biomedical engineers, pharmaceutical scientists, and manufacturers
Researchers working across the biosciences in fields of oncology, pharmacology
- Title of Book
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- About the editors
- Preface
- Drug Delivery Systems Landscape in Cancer Research (Vol. 1)
- Biomarker Landscape in Cancer Research (Vol. 2)
- Diagnostics Landscape in Cancer Research (Vol. 3)
- Preclinical Landscape in Cancer Research (Vol. 4)
- Clinical Landscape in Cancer Research (Vol. 5)
- 1. Liver cancer: Current and new drug delivery systems
- Introduction
- World statistics and risk factors
- Cellular mechanism
- Therapies available
- Pharmaceutical
- Biopharmaceutical
- Surgical
- Drug delivery systems in treating liver cancer
- Innovative therapies
- Liposomes
- Polymeric micelles
- Lipid nanoparticles
- Carbon nanotubes
- Dendrimers
- Lipid-polymer hybrid complexes
- Conclusion
- 2. Pancreatic cancer: Current and new drug delivery systems
- Introduction
- Challenges in the treatment of pancreatic cancer
- Lack of proper drug targeting technology due to challenging anatomical position of pancreas
- Absence of diagnostic biomarkers for early detection
- Immune suppression due to desmoplastic response of the tumor microenvironment in PC
- High-risk surgical procedures
- Recurrence with adjuvant chemotherapeutics
- Current approved drug therapies
- Everolimus
- Oxaliplatin
- Paclitaxel
- Nab-Paclitaxel
- Erlotinib hydrochloride
- 5-Fluorouracil
- Gemcitabine hydrochloride
- Mitomycin C
- Olaparib
- Sunitinib malate
- Irinotecan hydrochloride
- Cetuximab
- Nimotuzumab
- Selumetinib
- Folfirinox
- New drug delivery systems for pancreatic cancer
- Cyclin-dependent kinase
- MicroRNA-based therapy
- Oncolytic virus
- Nanomedicine
- Nanoparticles
- Micelles
- Immunotherapy approaches
- Photodynamic therapy
- Vaccines and drug conjugates
- Conclusion
- 3. Bone cancer: Current and new drug delivery systems
- Introduction
- Current therapies in bone cancer
- Chemotherapy
- Surgery
- Radiotherapy
- Current drug delivery strategies and systems
- New drug delivery systems in bone cancer treatment
- Targeted nanoparticle systems
- Implantable scaffold or composite systems
- Injectable Hydrogel systems
- Drug-device combination products
- Conclusion
- 4. Spleen cancer: Current and new drug delivery systems
- Introduction
- Factors affecting
- Genetic factors:
- Age:
- Underlying conditions:
- Immunosuppression:
- Radiation exposure:
- Chemical exposures:
- Prior spleen injury:
- Obesity:
- Cellular mechanism
- B-cell lymphoma origin:
- Chromosomal aberrations:
- NOTCH2 mutations:
- KLF2 mutations:
- TP53 mutations:
- Genetic diversity:
- B-cell receptor signaling:
- Microenvironment interactions:
- Metastasis:
- Therapies available for treating spleen cancer
- Pharmaceutical approach
- Chemotherapy:
- Targeted therapies:
- Immunotherapy:
- Radiopharmaceuticals:
- Steroids:
- Chemoradiotherapy:
- Hematopoietic stem cell transplantation:
- Pain management medications:
- Biopharmaceutical approach
- Surgery (splenectomy)
- Current marketed therapy
- Injection
- Biodegradable implants
- Oral medications
- Combination therapy
- Monoclonal antibodies
- Nanotechnology-based drug delivery systems
- Nanoparticles (liposomes, micelles):
- Polymer based drug delivery systems:
- Dendrimers:
- Nanosuspensions:
- Carbon nanotube:
- Magnetic nanoparticles:
- Conclusion
- 5. ENT cancer: Current and new drug delivery system
- Introduction
- World statistics
- Cellular mechanisms
- Genetic transformations leading to ENT carcinoma
- Cell proliferation, tumor growth and angiogenesis
- Tumor microenvironment
- Treatment and management of ENT cancer
- Surgery, radiation, chemotherapy, and immunotherapy
- Targeted therapy
- Liposomes:
- Nanoemulsion:
- Polymer lipid nanocomplex (LNs) used:
- Oro dispersible tablets used in ENT cancer:
- Bilayered tablets in the treatment of ENT cancer:
- Dendrimers:
- Solid lipid nanoparticles:
- Carbon nanotubes (CNTs):
- Conclusion
- 6. Brain cancer: Current and new drug delivery systems
- Introduction
- World statistics
- Cellular mechanism
- Disrupted developmental pathways
- PI3K (phosphoinositide 3-kinase)/mTOR (mammalian target of rapamycin) pathway
- MAPK (mitogen-activated protein kinase) pathway
- Chromatin remodeling factors
- Epigenetic modifications
- Notch signaling
- Wnt signaling
- Cellular invasion and migration
- Extracellular matrix (ECM) modification
- Calcium signaling
- Tubular networks
- Cell damage and inflammation
- Direct cell damage
- Increased intracranial pressure
- Genetic and epigenetic alterations
- Genetic mutations
- Epigenetic alterations
- Therapies available
- Pharmaceutical
- Biopharmaceutical
- Surgical
- Drug delivery systems in treating brain cancer
- Current marketed therapy
- Novel innovative therapies
- Lipid-based nanoparticles
- Conclusion
- 7. Skin cancer: Current and new drug delivery system
- Introduction
- Several barriers to skin cancer therapeutics
- Limitation of conventional dosage forms
- Current drug delivery system against skin cancer
- Nanocarriers against skin cancer
- Nanoemulsion
- Nanoparticles
- Nanogel
- Nanofiber
- Nanodispersion
- Solid lipid nanoparticle
- Vesicular drug delivery against skin cancer
- Liposome
- Niosome
- Ethosomes
- Transfersome
- Glycerosome
- Potential of recent approaches in combating skin cancer
- Photodynamic therapy (PDT) in skin cancer
- Potential of cold gas plasma against skin cancer
- Tumor-associated macrophages against skin cancer
- Microneedle patch
- Conclusion
- 8. Lung cancer: Current and new drug delivery systems
- Introduction
- World statistics and factors affecting lung cancer
- Cellular mechanisms
- Therapies available
- Pharmaceuticals
- Chemotherapy:
- Targeted therapy:
- Immunotherapy:
- Angiogenesis inhibitors:
- EGFR tyrosine kinase inhibitor (TKIs):
- ALK inhibitors:
- ROS1 inhibitors:
- Radiation therapy: This is basically of two types:
- Combination therapies:
- Biopharmaceuticals
- Monoclonal antibodies (mAbs):
- Immune checkpoint inhibitors:
- Biosimilars:
- Surgical
- Lobectomy:
- Wedge resection or segmentectomy:
- Pneumonectomy:
- Lymph node dissection or sampling:
- Minimally invasive surgery:
- Robotic-assisted surgery:
- Drug delivery systems in treating lung cancer
- Innovative therapies
- Liposomes
- Lipid nanoparticles
- Polymeric nanoparticles
- Carbon nanotubes
- Dendrimer
- Nanoemulsions
- Oral dosage forms
- Conclusion
- 9. Thorax cancer: Current and new drug delivery landscape
- Introduction
- Types
- Risk factors and causes
- Cellular mechanism of thorax cancer
- World statistics
- Advancements
- Traditional drug delivery methods
- Current drug delivery methods
- New drug delivery methods
- Polymeric NP
- Lipid NP
- Dendrimers
- Nanoemulsions
- Biopharmaceutical NP
- Challenges and limitations
- Conclusion
- 10. Kidney-adrenal: Current and new drug delivery systems
- Introduction
- World statistics and factors affecting
- Smoking & obesity
- Analgesics, diuretics & estrogens
- Von Hippel-Lindau syndrome (VHL)
- Other risk factors
- Cellular mechanism
- Therapies available
- Pharmaceutical therapies
- Biopharmaceutical therapies
- Surgical therapy
- Drug delivery systems in treating kidney-adrenal cancer
- Current marketed therapy
- New innovative therapies
- Liposomes
- Polymeric nanoparticles
- Lipid nanoparticles
- Carbon nanotubes
- Dendrimer
- Nanoemulsion
- Polymeric -lipid nano complex
- Orally disintegrating tablets (ODTs)
- Double layer tablet
- Other advances in drug delivery
- Drug targeting & challenges
- Conclusion
- 11. Urinary tract cancer: Current and new drug delivery system
- Introduction
- World Statistics
- Factors affecting urinary cancer
- Tobacco
- Age & gender
- Infections and pathogens
- BMI (body mass index)
- Cellular mechanism
- Therapies available
- Pharmaceutical therapy
- Chemotherapy
- Immunotherapy
- Gene therapy
- Biopharmaceutical therapy
- Targeted therapy
- Fibroblast growth factor receptor
- Epidermal growth factor receptor
- Human epidermal growth factor receptor 2
- Surgical therapy
- Drug delivery systems in treating urinary bladder cancer
- Current marketed therapy:
- Intravesical chemotherapy:
- Immunotherapy:
- Intravesical solutions:
- Hydrogel solutions:
- Injectable therapies
- Chemotherapy agents:
- Targeted therapies:
- Pain management:
- New innovative therapies
- Liposomes and lipid nanoparticles
- Polymeric nanoparticles
- Dendrimers
- Carbon nanotubes (CNTs)
- Nanoemulsions
- Polymer lipid nanocomplexes
- ODT
- Double layer tablet
- Other advances in drug delivery
- Drug target & challenges
- Conclusion
- 12. Breast cancer: Drug delivery system landscape
- Introduction
- Ductal carcinoma in situ (DCIS):
- Invasive ductal carcinoma (IDC):
- Invasive lobular carcinoma (ILC):
- Triple-negative breast cancer:
- HER2-positive breast cancer:
- Inflammatory breast cancer:
- Metastatic breast cancer:
- Importance of effective drug delivery systems
- Overview of drug delivery systems
- Oral delivery systems
- Intravenous delivery systems
- Targeted delivery systems
- Monoclonal antibodies:
- Antibody-drug conjugates (ADCs):
- Liposomal delivery systems
- Liposomal chemotherapy:
- Polymeric nanoparticles
- Polymeric nanoparticles:
- Implantable delivery systems
- Drug-eluting implants:
- Hormonal delivery systems
- Hormonal therapies:
- Inhalation delivery systems
- Inhalable nanoparticles:
- Intratumoral delivery systems
- Direct injection:
- Breast cancer pharma marker
- Conclusion
- 13. Colorectal cancer: Current and new drug delivery systems
- Introduction
- Factors affecting colorectal cancer
- Cellular mechanism of colorectal cancer
- Initiation
- Adenoma formation
- Genetic mutations
- Epigenetic changes
- Tumor angiogenesis
- Metastasis
- Immune system invasion
- Therapies used for colorectal cancer
- Pharmaceutical therapies
- Chemotherapy
- Targeted therapy
- Oral targeted
- Antiinflammatory drug
- Injections
- Immunotherapy
- Marketed drugs
- Radiopharmaceuticals
- Nanoparticle based drug delivery systems
- Biopharmaceutical therapies
- Monoclonal antibodies
- Immunotherapy
- VEGF-targeted therapies and HER2-targeted therapy
- VEGF-targeted therapies
- HER2-targeted therapy
- Surgical therapy
- Conclusion
- 14. Blood cancer: Current and new drug delivery systems
- Introduction to blood cancer
- World statistics and factors affecting blood cancer
- Cellular mechanisms underlying blood cancer
- Therapies available
- Pharmaceutical therapies for blood cancer
- Biopharmaceutical therapies for blood cancer
- Surgical options
- Drug delivery systems in the treatment of blood cancer
- Current marketed therapies
- New innovative therapies
- Liposomes
- Passive targeting: The enhanced permeability and retention (EPR) effect:
- Active targeting:
- Chemotherapy:
- Nucleic acid therapeutics:
- Immunotherapy:
- Polymeric nanoparticles
- Enhanced permeability and retention (EPR) effect:
- Active targeting:
- Chemotherapy:
- Immunotherapy:
- Gene therapy:
- Lipid nanoparticles
- Enhanced permeability and retention (EPR) effect:
- Active targeting:
- Chemotherapy:
- Immunotherapy:
- Gene therapy:
- Carbon nanotubes
- Cellular uptake:
- Targeted delivery:
- Multifunctional platforms:
- Chemotherapy:
- Imaging:
- Challenges and future directions
- Dendrimer
- Controlled drug release:
- Targeted delivery:
- Multifunctional platforms:
- Chemotherapy:
- Immunotherapy:
- Challenges and future directions
- Nanoemulsions
- Enhanced cellular uptake:
- Targeted delivery:
- Controlled drug release:
- Chemotherapy:
- Combination therapy:
- Challenges and future directions
- Polymer-lipid nanocomplex
- Enhanced stability and biocompatibility:
- Controlled drug release:
- Targeted delivery:
- Chemotherapy:
- Combination therapy:
- Challenges and future directions
- ODT (Orally disintegrating tablets or Oro dispersible tablets)
- Rapid disintegration and dissolution:
- Enhanced patient compliance:
- Chemotherapy:
- Targeted therapy:
- Challenges and future directions
- Double layer tablet
- Dual-release mechanism:
- Improved bioavailability:
- Chemotherapy:
- Targeted therapy:
- Challenges and future directions
- Other advances in drug delivery
- Conclusion
- 15. Prostate cancer: Current and new drug delivery systems
- Introduction
- World statistics and factors affecting
- Cellular mechanism
- Therapies available
- Pharmaceutical
- Biopharmaceutical
- Androgen synthesis inhibitors:
- Immunotherapy
- Surgical
- Radical prostatectomy:
- Robot-assisted laparoscopic prostatectomy (RALP):
- Transurethral resection of the prostate (TURP):
- Cryotherapy:
- Drug delivery systems
- Current marketed therapy
- LHRH agonists and antagonists:
- Antiandrogens:
- Chemotherapy agents:
- Radioisotopes (radium-223):
- New innovative therapies
- Liposomes
- Polymeric nanoparticles
- Dendrimer nanoparticles
- Chitosan nanoparticles
- Magnetic nanoparticles
- Solid lipid nanoparticles
- α-enolase-targeted drug delivery system
- 2-Methoxystradiol loaded zeolite nanoparticles
- Antibody and aptamer mediated drug delivery
- Nanoparticle-based RNA-DNA hybrid aptamer
- Self-nano-emulsifying drug delivery system (SNEDDS)
- Nanoemulsion
- Peptide conjugated delivery systems
- Macrophage mediated biomimetic delivery system
- Ultrasound enhanced drug delivery
- Polyarginine-disulfide linked PEI nanocarrier for delivery of microRNA
- Lactoferrin-bearing gold nanocages
- Lactoferrin- and dendrimer-Bearing gold nanocages
- Conclusion
- 16. Ovarian cancer: Current and new drug delivery system
- Introduction
- Factors affecting ovarian cancer
- Age
- Genetic factors
- Family history
- Personal history
- Treatment history
- Endometriosis
- Obesity
- Environmental factors
- Lifestyle factors
- Cellular mechanism
- Genetic mutations:
- Cell signaling pathways:
- DNA repair deficiency:
- Epithelial-mesenchymal transition (EMT):
- Angiogenesis:
- Immune evasion:
- Tumor microenvironment:
- Metastasis:
- Therapeutic approach
- Pharmaceutical approach
- Biopharmaceutical approach
- Surgical therapy
- Conclusion
- 17. Stomach and intestinal cancer: Current and new drug delivery systems
- Introduction
- Worldwide incidence trends
- Cellular mechanism
- Nonpathogenic influence
- Pathogenic influence
- Available therapies for stomach and intestinal cancer
- Conventional therapy
- Targeted therapy
- Surgical therapy
- Radiotherapy
- Current marketed therapy
- Innovative therapies for stomach and intestinal cancer
- Nano based drug delivery
- Patented techniques
- Challenges in the development of novel drug delivery systems of stomach and intestinal cancer
- Drug release interval
- Specificity targeting
- Transmission and accumulation in tissues
- Conclusion
- 18. Oral cancer: Current and new drug delivery system
- Introduction
- World statistics
- Cellular mechanism
- Therapies available
- Pharmaceutical
- Biopharmaceutical
- Surgical treatments
- Drug delivery systems in treating OC
- Current marketed therapy
- Nanotechnology based drug delivery system
- Liposomes
- Polymeric nanoparticles
- Lipid nanoparticles
- Carbon nanotubes
- Dendrimers
- Nanoemulsions
- Other advances in drug delivery
- Conclusion
- 19. Ocular cancer—Current and new drug delivery systems
- Introduction
- World statistics
- Cellular mechanism of ocular cancer
- Therapies available for ocular cancer
- Pharmaceutical therapy
- Biopharmaceutical therapy
- Surgical options
- Anatomical barriers in drug delivery
- Drug delivery systems in treating ocular cancer
- Current marketed therapy
- New innovative therapies
- Liposomes
- Polymeric nanoparticles
- Lipid nanoparticles
- Carbon nanotubes
- Dendrimers
- Microemulsions
- Polymer-lipid nanocomplex
- Other advances in drug delivery system
- Conclusion
- Index
- Edition: 1
- Published: April 3, 2025
- Imprint: Academic Press
- No. of pages: 504
- Language: English
- Paperback ISBN: 9780443291685
- eBook ISBN: 9780443291692
RS
Ranjita Shegokar
Ranjita Shegokar holds a Ph.D. degree in Pharmaceutical Technology from the SNDT University, India, and has been a postdoctoral researcher in the Department of Pharmaceutics, Biopharmaceutics and NutriCosmetics at the Free University of Berlin, Germany. Currently, she serves as Chief Scientific Officer (CSO) at Capnopharm GmbH, Germany. She has authored several research articles, book chapters, and presented her research in many national/international conferences. She has filed multiple patent applications in the area of drug delivery and targeting. Besides that, she has edited many trending books in the area of pharmaceutical nanotechnology and drug delivery aspects. For her research, she has received many prestigious national and international awards among them include recently received prestigious German Innovation Award 2022. Her areas of interest include polymeric nanoparticles, nanocrystals, lipid nanoparticles (SLNs/NLCs), nanoemulsions, cancer drug targeting and the role of excipients in delivery systems. (www.ranjitas.com)
Affiliations and expertise
Postdoctoral Researcher, Department of Pharmaceutics, Biopharmaceutics and NutriCosmetics, Free University of Berlin, GermanyYP
Yashwant Pathak
Yashwant Pathak is a Professor and Associate Dean for faculty affairs at the Taneja College of Pharmacy at the University of South Florida, Tampa, USA. Prof. Pathak is also an Adjunct Professor at the Faculty of Pharmacy, Airlangga University, Surabaya, Indonesia. His area of research is in health care education, nanotechnology, drug delivery systems, and nutraceuticals.
Affiliations and expertise
Professor and Associate Dean, Faculty Affairs, College of Pharmacy, University of South Florida, Tampa, USARead Drug Delivery Landscape in Cancer Research on ScienceDirect